IMNN-001 Ph 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift September 23, 2025
Positive Ph 3 Results Show Giredestrant Significantly Improved PFS in ER-Positive Advanced Breast Cancer September 23, 2025
Ph 1/2a Plixorafenib Data Demonstrated Prolonged Duration of Effect in BRAF Altered Thyroid Cancers September 23, 2025
Positive Interim Efficacy Analysis of Ph 2 Trial of ENV105 in Advanced Prostate Cancer with Median PFS of Over One Year Announced September 23, 2025
Patients With Aggressive Brain and Advanced Liver Cancers Treated with PIC monotherapy Reach Five Years of Durable RFS September 23, 2025
Final results from OPTIMIZE-1 trial of mitazalimab – mFOLFIRINOX combo in 1L metastatic pancreatic cancer patients announced September 23, 2025
CHMP recommends EU approval of SC formulation of Lunsumio for people with R/R follicular lymphoma September 23, 2025
Two Positive EU CHMP Opinions for KEYTRUDA, for SC Administration and for New Indication for Earlier-Stage Head and Neck Cancer September 23, 2025
Type A meeting with FDA completed to discuss the CRL for RP1 + nivolumab BLA in melanoma September 23, 2025
Revuforj® (revumenib) Included in NCCN Guidelines for the Treatment of R/R NPM1 Mutated AML September 23, 2025
European Commission Approves VORANIGO® (vorasidenib) for Grade 2 IDH-Mutant Glioma September 23, 2025
